Epidemiological and clinical characteristics of discharged patients infected with SARS-CoV-2 on the Qinghai Plateau.
COVID-19
SARS-CoV-2
clinical characteristics
epidemiological
plateau
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
07
04
2020
accepted:
17
05
2020
pubmed:
22
5
2020
medline:
29
12
2020
entrez:
22
5
2020
Statut:
ppublish
Résumé
Since the outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, a series of confirmed cases of COVID-19 were found on the Qinghai-Tibet plateau. We aimed to describe the epidemiological, clinical characteristics, and outcomes of all confirmed cases in Qinghai, a province at high altitude. The region had no sustained local transmission. Of all 18 patients with confirmed SARS-CoV-2 infection, 15 patients comprising four transmission clusters were identified. Three patients were infected by direct contact without travel history to Wuhan. Of 18 patients, 10 patients showed bilateral pneumonia and two patients showed no abnormalities. Three patients with comorbidities such as hypertension, liver diseases, or diabetes developed severe illness. High C-reactive protein levels and elevations of both alanine aminotransferase and aspartate aminotransferase were observed in three severely ill patients on admission. All 18 patients were eventually discharged, including the three severe patients who recovered after treatment with noninvasive mechanical ventilation, convalescent plasma, and other therapies. Our findings confirmed human-to-human transmission of SARS-CoV-2 in clusters. Patients with comorbidities are more likely to develop severe illness.
Identifiants
pubmed: 32437017
doi: 10.1002/jmv.26032
pmc: PMC7280617
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2528-2535Subventions
Organisme : QingHai Department of Science and Technology
ID : 2020-SF-158
Pays : International
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Intensive Care Med. 2001 Sep;27(9):1539-46
pubmed: 11685349
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
J Med Virol. 2020 Nov;92(11):2528-2535
pubmed: 32437017
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013